SLC5A2 and hydrops fetalis: However, studies of the effect of SGLT2 inhibitors on skeletal muscle mass, strength and exercise capacity in patients with HF are lacking; a recent meta-analysis showed that SGLT2 inhibitors may improve health-related quality of life (HRQoL) and exercise capacity in patients with CHF, which could lead to an increase in physical activity with benefits for muscle mass [35].